t(4;14) by FISH Test in Pakistan at Chughtai Lab

t(4;14) by FISH (Research Purpose only) at Chughtai Lab

The t(4;14) by FISH (Research Purpose only) test at Chughtai Lab is a highly specialized molecular cytogenetic analysis designed to detect a specific chromosomal translocation between chromosome 4 and chromosome 14. This translocation, designated as t(4;14)(p16.3;q32), is of paramount clinical and research significance, particularly in the field of hematological oncology. It is most commonly associated with plasma cell dyscrasias, most notably multiple myeloma. By utilizing Fluorescence In Situ Hybridization (FISH) technology, pathologists and researchers can identify this genetic anomaly with high sensitivity and specificity, even in non-dividing cells. Chughtai Lab, a premier diagnostic institution in Pakistan, offers this advanced molecular assay to support clinical research, academic investigations, and comprehensive prognostic profiling for patients undergoing evaluation for hematological malignancies.

Fluorescence In Situ Hybridization (FISH) works by using fluorescently labeled DNA probes that are complementary to specific genomic sequences on chromosomes 4 and 14. Specifically, the probes target the FGFR3 (fibroblast growth factor receptor 3) gene region on chromosome 4p16.3 and the IGH (immunoglobulin heavy chain) locus on chromosome 14q32. When a translocation occurs, these two gene regions fuse together. Under a specialized fluorescence microscope, this fusion is visualized as overlapping or adjacent fluorescent signals of different colors (typically green and orange, which merge to form a yellow signal). Identifying this fusion is crucial because the t(4;14) translocation leads to the deregulation and overexpression of the FGFR3 and MMSET (multiple myeloma SET domain) genes, which play a critical role in the pathogenesis, cellular proliferation, and chemotherapy resistance of abnormal plasma cells.

While this specific assay is designated for “Research Purpose only,” its diagnostic value in modern hemato-oncology is immense. In clinical research settings, identifying the t(4;14) translocation is vital for risk stratification. Multiple myeloma is a highly heterogeneous disease, and cytogenetic abnormalities are the strongest prognostic factors. The presence of t(4;14) is universally recognized as a high-risk cytogenetic marker, associated with an aggressive disease course, shorter overall survival, and a higher likelihood of early relapse. Understanding the prevalence and impact of this marker within the Pakistani population through Chughtai Lab’s extensive diagnostic network helps researchers and clinicians develop targeted therapeutic strategies and participate in global clinical trials aimed at overcoming the adverse prognosis associated with this genetic profile.

Clinical Procedure: What to Expect

Patient Preparation

Proper preparation is essential to ensure sample integrity and accurate molecular analysis. Patients undergoing the t(4;14) by FISH test at Chughtai Lab should observe the following guidelines:

• No Fasting Required: There is generally no need to fast before this test. Patients can eat and drink normally unless instructed otherwise by their physician for concurrent tests.
• Medical History Disclosure: Inform the healthcare provider and laboratory staff about all ongoing medications, especially blood thinners (anticoagulants) like aspirin, warfarin, or heparin, as these can affect bleeding during sample collection.
• Prior Therapies: Disclose any recent chemotherapy, radiotherapy, or bone marrow transplants, as these treatments can significantly alter plasma cell populations and cytogenetic findings.
• Consent and Documentation: Since this test is designated for research purposes, patients or guardians may be required to sign a specialized consent form. Ensure all referral forms from the oncologist are complete and clearly state the clinical suspicion.
• Hydration: Staying well-hydrated is recommended, especially if a peripheral blood sample is being collected, as it makes venipuncture easier.

During the Procedure

The procedure for the t(4;14) by FISH test involves sample collection, transport, and sophisticated laboratory processing. Depending on the clinical scenario, the sample may be peripheral blood or bone marrow aspirate:

• Sample Collection (Venipuncture): If peripheral blood is used, a phlebotomist will cleanse a vein in your arm with an antiseptic, apply a tourniquet, and insert a sterile needle to draw blood into a green-top (sodium heparin) tube. Sodium heparin is the preferred anticoagulant for cytogenetic studies as it preserves cell viability.
• Sample Collection (Bone Marrow Aspiration): If a bone marrow sample is required, this minor surgical procedure is performed by a hematologist or trained oncologist. The site (usually the posterior iliac crest of the hip) is numbed with a local anesthetic. A specialized needle is inserted into the bone, and a small amount of liquid bone marrow is aspirated.
• Laboratory Processing: Once the sample reaches Chughtai Lab’s state-of-the-art molecular diagnostics department, plasma cells are often enriched (sometimes using CD138+ magnetic beads) to increase the sensitivity of the FISH assay.
• Hybridization and Analysis: The cells are fixed onto slides, denatured, and hybridized with the specific IGH/FGFR3 dual-color, dual-fusion probes. After overnight incubation and washing, a highly trained cytogeneticist analyzes the slides under a fluorescence microscope, counting a minimum of 100 to 200 interphase nuclei to determine the percentage of cells carrying the translocation.
• Safety and Comfort: Venipuncture is quick and associated with minimal discomfort. Bone marrow aspiration may cause a brief, deep aching sensation but is performed under local anesthesia to maximize patient comfort.

When is a t(4;14) by FISH Performed?

1. Risk Stratification in Multiple Myeloma

Physicians request the t(4;14) by FISH test primarily during the initial diagnostic workup of patients newly diagnosed with multiple myeloma. Multiple myeloma exhibits diverse clinical outcomes, and identifying cytogenetic abnormalities is the gold standard for determining whether a patient has standard-risk or high-risk disease. Detecting the t(4;14) translocation allows oncologists to classify the patient into a high-risk category, which directly influences the intensity of the treatment strategy, such as recommending early autologous stem cell transplantation or specific proteasome inhibitor-based induction regimens.

2. Evaluation of Smoldering Multiple Myeloma

Smoldering multiple myeloma (SMM) is an asymptomatic precursor stage of active myeloma. Predicting which SMM patients will progress to active, symptomatic disease is a major clinical challenge. The presence of high-risk cytogenetic markers, including the t(4;14) translocation, is a strong predictor of rapid progression. Clinicians utilize this test to identify high-risk SMM patients who might benefit from early therapeutic intervention or close, high-frequency clinical monitoring within clinical trials.

3. Clinical Trials and Hematoncology Research

Because this test is designated for research purposes, it is frequently performed as part of clinical trials, academic research studies, and epidemiological surveys in Pakistan. Researchers at Chughtai Lab and collaborating academic institutions use this assay to study the molecular epidemiology of plasma cell disorders in the local population. It helps evaluate the efficacy of novel targeted therapies, such as FGFR3 inhibitors or advanced immunotherapies, by correlating clinical responses with the patient’s specific cytogenetic profile.

4. Investigating Unexplained Bone Pain and Cytopenias

When patients present with unexplained, persistent bone pain, pathological fractures, recurrent infections, renal insufficiency, or cytopenias (anemia, thrombocytopenia), a plasma cell dyscrasia is often suspected. If preliminary tests like serum protein electrophoresis (SPEP) or immunofixation show abnormal monoclonal proteins (M-spike), the t(4;14) FISH test is performed alongside bone marrow biopsy to confirm the clonal nature of the plasma cells and evaluate the underlying genetic drivers of the disease.

5. Monitoring Minimal Residual Disease (MRD) and Relapse

In patients with a known history of t(4;14)-positive multiple myeloma, this test can be performed periodically to monitor treatment response and detect early signs of disease relapse. While highly sensitive molecular methods like Next-Generation Sequencing (NGS) or flow cytometry are preferred for deep MRD assessment, FISH remains a valuable tool to detect the re-emergence of the specific high-risk clone, allowing oncologists to adjust salvage therapies before clinical relapse manifest.

What Does a t(4;14) by FISH Detect?

The t(4;14) by FISH test is designed to detect and quantify specific genetic and technical parameters within the submitted sample. These include:

• Presence of t(4;14)(p16.3;q32) Translocation: Confirms the physical fusion of the IGH and FGFR3 gene regions.
• Percentage of Positive Nuclei: Quantifies the proportion of analyzed plasma cells that harbor the translocation, which represents the clone size.
• Normal Diploid Pattern: Identifies cells with two normal green (FGFR3) and two normal orange (IGH) signals, indicating a normal genetic complement for these loci.
• Atypical Signal Patterns: Detects non-classical fusion patterns, which may indicate complex rearrangements, insertions, or variant translocations.
• FGFR3 Gene Amplification: Identifies extra copies of the chromosome 4 region containing the FGFR3 gene.
• IGH Gene Rearrangements: Detects rearrangements of the IGH locus with partners other than chromosome 4, prompting further testing.
• Monosomy 4 or Monosomy 14: Identifies the loss of an entire chromosome 4 or 14, which can co-occur in complex karyotypes.
• Trisomy of Chromosome 4 or 14: Detects extra copies of these chromosomes, often associated with hyperdiploid multiple myeloma, which generally carries a better prognosis.
• Clonal Heterogeneity: Reveals whether the translocation is present in all abnormal plasma cells or only in a subclone, reflecting the evolutionary stage of the disease.
• Sample Cellularity: Assesses whether the submitted specimen contains a sufficient number of nucleated cells for reliable cytogenetic analysis.
• Plasma Cell Enrichment Success: Verifies if the CD138+ selection process successfully concentrated the target plasma cells.
• Hybridization Efficiency: Evaluates the technical quality of the assay, ensuring the fluorescent probes bound correctly to the target DNA.
• Background Fluorescence Levels: Monitors technical noise to ensure clear differentiation between true signals and artifacts.
• Probe Signal Intensity: Measures the brightness of the fluorescent signals to rule out probe degradation.
• Co-existing Deletion of 17p (TP53): Often evaluated in parallel panels to check for other high-risk markers.
• Co-existing t(11;14) Translocation: Evaluated to rule out other primary translocations that are mutually exclusive with t(4;14).
• Co-existing t(14;16) Translocation: Checked to differentiate between different high-risk cytogenetic subgroups.
• Chromosome 1q Gain/Amplification: Often assessed alongside t(4;14) as it frequently co-occurs and further worsens prognosis.
• Chromosome 1p Deletion: Another co-existing marker that influences risk stratification in plasma cell disorders.
• Nuclear Morphology: Allows visual assessment of the size and shape of the interphase nuclei being analyzed.
• Artifactual Signal Overlap: Distinguishes true genetic fusions from random physical overlapping of signals in a three-dimensional nucleus.
• Technical Control Validation: Confirms that internal control probes (such as centromeric probes) yielded expected results, validating the run.

Turnaround Time and Report Access at Chughtai Lab

Because the t(4;14) by FISH test is a highly specialized molecular cytogenetic assay requiring meticulous laboratory processing, probe hybridization, and expert microscopic analysis, the turnaround time is typically longer than standard blood tests. At Chughtai Lab, the results are generally available within 7 to 10 working days. This timeline ensures that the cytogenetics team has sufficient time to perform plasma cell enrichment, execute the hybridization protocol, and have a consultant pathologist review and interpret the complex fluorescent signal patterns.

Chughtai Lab offers seamless and convenient access to diagnostic reports. Once the report is finalized and signed off by the consultant pathologist, patients and referring physicians receive an automated SMS notification. Reports can be downloaded directly from the official Chughtai Lab website by entering the case number and password provided on the sample collection receipt. Additionally, patients can access their complete diagnostic history, including this FISH report, via the user-friendly Chughtai Lab Mobile App, available on both iOS and Android platforms. For patients who prefer physical copies, reports can be collected from any of Chughtai Lab’s numerous collection centers located across Pakistan.

t(4;14) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
t(4;14) Fusion Signals	No fusion signals detected (separate green and orange signals)	Presence of fusion signals (overlapping green/orange or yellow signals)
Percentage of Positive Cells	0% (Below the laboratory’s established cut-off threshold)	Elevated percentage (e.g., >10% of analyzed nuclei positive for fusion)
FGFR3 Signal Count	Two distinct signals per nucleus (diploid state)	Single signal (deletion/monosomy) or three or more signals (amplification/trisomy)
IGH Signal Count	Two distinct signals per nucleus (diploid state)	Single signal (deletion) or multiple signals (rearrangement/polyploidy)
Clonal Distribution	Homogeneous normal cell population	Clonal heterogeneity with distinct sub-populations of translocated cells
Hybridization Quality	High efficiency, clear signals, low background noise	Poor hybridization, weak signals, or high background (requires repeat testing)
CD138+ Enrichment Status	Sufficient plasma cell yield for analysis	Inadequate plasma cell yield (may occur in samples with low tumor burden)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for t(4;14) by FISH?

• Experienced Healthcare Professionals: Chughtai Lab boasts a team of highly qualified consultant pathologists, cytogeneticists, and molecular biologists with extensive experience in interpreting complex FISH assays.
• Patient-Focused Care: The laboratory prioritizes patient comfort, safety, and clear communication throughout the sample collection and reporting process.
• Quality Diagnostic Services: Operating with strict internal and external quality control protocols, Chughtai Lab ensures the highest level of accuracy and reproducibility in molecular testing.
• Professional Reporting: Reports are structured clearly, providing detailed quantitative data, signal patterns, and clinical interpretations that are easy for oncologists to utilize.
• Modern Diagnostic Approach: Utilizing state-of-the-art fluorescence microscopes, high-quality dual-fusion probes, and advanced cell separation technologies.
• Comfortable Environment: All collection centers and main labs are designed to provide a clean, professional, and welcoming environment for patients.
• Convenient Location: With a vast network of collection centers across Lahore, Karachi, Islamabad, and other major cities in Pakistan, accessing specialized testing is highly convenient.
• Commitment to Accurate Diagnosis: Chughtai Lab is dedicated to supporting the medical community with cutting-edge diagnostics, contributing significantly to oncology research and patient management in Pakistan.